-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic rhinitis with nasal polyps (CRSwNP) is characterized by excessive IgE secretion and eosinophil inflammation
Adult patients with CRSwNP and insufficient response to intranasal corticosteroids were randomly (1:1) assigned to omalizumab or placebo and oral mometasone for 24 weeks
The results showed that patients with POLYP 1 (n = 138) and POLYP 2 (n = 127) showed severe CRSwNP and significant quality of life impairment, with an average NPS higher than 6, and a SNOT-22 score of about 60
In summary, omalizumab significantly improved the endoscopic, clinical and patient-reported results of severe CRSwNP with insufficient response to intranasal corticosteroids, and it was well tolerated
Original source:
Philippe Gevaert, Theodore A Omachi, et al.
Efficacy and safety of omalizumab in nasal polyposis : 2 randomized phase 3 trials
in this message